Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

01-03-2010 | Article

The relative contribution of efflux and target gene mutations to fluoroquinolone resistance in recent clinical isolates of Pseudomonas aeruginosa

Authors: S. A. Dunham, C. J. McPherson, A. A. Miller

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 3/2010

Abstract

The clinical utility of fluoroquinolones (FQs) for the treatment of Pseudomonas aeruginosa (PA) and other serious Gram-negative infections is currently decreasing due to the rapid emergence of resistance. Because previous studies have shown that efflux is a common mechanism contributing to FQ resistance in PA, one suggested approach to extend the longevity of this class of drugs is combination therapy with an efflux pump inhibitor (EPI). In order to determine the viability of this approach, it is necessary to understand the relative contribution of efflux- vs. target-mediated mechanisms of FQ resistance in the clinic. A set of 26 recent PA clinical isolates were characterized for antibiotic resistance profiles, efflux pump expression, topoisomerase mutations, and FQ susceptibility with and without an EPI. The contribution of OprM to the overall antibiotic resistance was assessed in a subset of these strains. Our results suggest that the co-administration of an EPI with FQs or other antibiotics currently in use would not be sufficient to combat the complexity of resistance mechanisms now present in many clinical isolates.

Bonomo RA, Szabo D (2006) Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 43:S49–S56CrossRefPubMed

Hancock REW, Speert DP (2000) Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug Resist Updat 3:247–255CrossRefPubMed

Mesaros N, Nordmann P, Plésiat P et al (2007) Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 13:560–578CrossRefPubMed

Rahal JJ (2006) Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 43:S95–S99CrossRefPubMed

Rice LB (2006) Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 43:S100–S105CrossRefPubMed

Rossolini GM, Mantengoli E (2005) Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 11(Suppl 4):17–32CrossRefPubMed

Bratu S, Quale J, Cebular S et al (2005) Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin B. Eur J Clin Microbiol Infect Dis 24:196–201CrossRefPubMed

Henrichfreise B, Wiegand I, Pfister W et al (2007) Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. Antimicrob Agents Chemother 51:4062–4070CrossRefPubMed

Obritsch MD, Fish DN, MacLaren R et al (2005) Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 25:1353–1364CrossRefPubMed

10.

Polk RE, Johnson CK, McClish D et al (2004) Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis 39:497–503CrossRefPubMed

11.

Mouneimné H, Robert J, Jarlier V et al (1999) Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 43:62–66PubMed

12.

Wolfson JS, Hooper DC (1989) Bacterial resistance to quinolones: mechanisms and clinical importance. Rev Infect Dis 11:S906–S968

13.

Oh H, Stenhoff J, Jalal S et al (2003) Role of efflux pumps and mutations in genes for topoisomerases II and IV in fluoroquinolone-resistant Pseudomonas aeruginosa strains. Microb Drug Resist 9:323–328CrossRefPubMed

14.

Aeschlimann JR (2003) The role of multidrug efflux pumps in the antibiotic resistance of Pseudomonas aeruginosa and other gram-negative bacteria. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 23:916–924CrossRefPubMed

15.

Kriengkauykiat J, Porter E, Lomovskaya O et al (2005) Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 49:565–570CrossRefPubMed

16.

Köhler T, Michéa-Hamzehpour M, Plésiat P et al (1997) Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa. Antimicrob Agents Chemother 41:2540–2543PubMed

17.

Masuda N, Sakagawa E, Ohya S et al (2000) Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 44:3322–3327CrossRefPubMed

18.

Poole K, Gotoh N, Tsujimoto H et al (1996) Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa. Mol Microbiol 21:713–724CrossRefPubMed

19.

Poole K, Srikumar R (2001) Multidrug efflux in Pseudomonas aeruginosa: components, mechanisms and clinical significance. Curr Top Med Chem 1:59–71CrossRefPubMed

20.

Dumas J-L, van Delden C, Perron K et al (2006) Analysis of antibiotic resistance gene expression in Pseudomonas aeruginosa by quantitative real-time-PCR. FEMS Microbiol Lett 254:217–225CrossRefPubMed

21.

Fukuda H, Hosaka M, Iyobe S et al (1995) NfxC-type quinolone resistance in a clinical isolate of Pseudomonas aeruginosa. Antimicrob Agents Chemother 39:790–792PubMed

22.

Higgins PG, Fluit AC, Milatovic D et al (2003) Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents 21:409–413CrossRefPubMed

23.

Jalal S, Wretlind B (1998) Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa. Microb Drug Resist 4:257–261CrossRefPubMed

24.

Sobel ML, Hocquet D, Cao L et al (2005) Mutations in PA3574 (nalD) lead to increased mexab-oprm expression and multidrug resistance in laboratory and clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 49:1782–1786CrossRefPubMed

25.

Hocquet D, Roussel-Delvallez M, Cavallo J-D et al (2007) MexAB-OprM- and MexXY-overproducing mutants are very prevalent among clinical strains of Pseudomonas aeruginosa with reduced susceptibility to ticarcillin. Antimicrob Agents Chemother 51:1582–1583CrossRefPubMed

26.

Nakajima A, Sugimoto Y, Yoneyama H et al (2002) High-level fluoroquinolone resistance in Pseudomonas aeruginosa due to interplay of the MexAB-OprM efflux pump and the DNA gyrase mutation. Microbiol Immunol 46:391–395PubMed

27.

Amaral L, Pagès J-M (2008) Control and regulation of permeability of MDR bacterial pathogens to antibiotics. Curr Drug Targets 9:718CrossRefPubMed

28.

Barrett JF (2001) MC-207110 Daiichi Seiyaku/Microcide Pharmaceuticals. Curr Opin Investig Drugs 2:212–215PubMed

29.

Kaatz GW (2002) Inhibition of bacterial efflux pumps: a new strategy to combat increasing antimicrobial agent resistance. Expert Opin Emerg Drugs 7:223–233CrossRefPubMed

30.

Lomovskaya O, Warren MS, Lee A et al (2001) Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 45:105–116CrossRefPubMed

31.

Lomovskaya O, Bostian KA (2006) Practical applications and feasibility of efflux pump inhibitors in the clinic—a vision for applied use. Biochem Pharmacol 71:910–918CrossRefPubMed

32.

Lomovskaya O, Zgurskaya HI, Totrov M et al (2007) Waltzing transporters and ‘the dance macabre’ between humans and bacteria. Nat Rev Drug Discov 6:56–65CrossRefPubMed

33.

Griffith D, Lomovskaya O, Lee V et al (2000) Potentiation of levofloxacin by MC-02595, a broad-spectrum efflux pump inhibitor (EPI) in mouse models of infection due to Pseudomonas aeruginosa with combinations of different Mex pump expression and gyrA mutation. In: Interscience Conference on Antimicrobial Agents in Chemotherapy, Toronto, Ontario, Canada, September 2000

34.

Lomovskaya O, Lee A, Hoshino K et al (1999) Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 43:1340–1346PubMed

35.

Jung R, Fish DN, Obritsch MD et al (2004) Surveillance of multi-drug resistant Pseudomonas aeruginosa in an urban tertiary-care teaching hospital. J Hosp Infect 57:105–111CrossRefPubMed

36.

Pournaras S, Maniati M, Spanakis N et al (2005) Spread of efflux pump-overexpressing, non-metallo-beta-lactamase-producing, meropenem-resistant but ceftazidime-susceptible Pseudomonas aeruginosa in a region with blaVIM endemicity. J Antimicrob Chemother 56:761–764CrossRefPubMed

37.

Yoshida K, Nakayama K, Ohtsuka M et al (2007) MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate. Bioorg Med Chem 15:7087–7097CrossRefPubMed

38.

Stover CK, Pham XQ, Erwin AL et al (2000) Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406:959–964CrossRefPubMed

39.

Simon R, Priefer U, Pühler A (1983) A broad host range mobilization system for in vivo genetic engineering: transposon mutagenesis in Gram negative bacteria. Biotechnology 1:784–791CrossRef

40.

Approved Standard M7-A2 (1990) In: Standards. NCfCL, ed. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS, Villanova

41.

Mesaros N, Glupczynski Y, Avrain L et al (2007) A combined phenotypic and genotypic method for the detection of Mex efflux pumps in Pseudomonas aeruginosa. J Antimicrob Chemother 59:378–386CrossRefPubMed

42.

Okamoto K, Gotoh N, Nishino T (2002) Extrusion of penem antibiotics by multicomponent efflux systems MexAB-OprM, MexCD-OprJ, and MexXY-OprM of Pseudomonas aeruginosa. Antimicrob Agents Chemother 46:2696–2699CrossRefPubMed

43.

Okamoto K, Gotoh N, Nishino T (2002) Alterations of susceptibility of Pseudomonas aeruginosa by overproduction of multidrug efflux systems, MexAB-OprM, MexCD-OprJ, and MexXY/OprM to carbapenems: substrate specificities of the efflux systems. J Infect Chemother 8:371–373CrossRefPubMed

44.

Masuda N, Gotoh N, Ohya S et al (1996) Quantitative correlation between susceptibility and OprJ production in NfxB mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother 40:909–913PubMed

45.

Köhler T, Michéa-Hamzehpour M, Henze U et al (1997) Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol 23:345–354CrossRefPubMed

46.

Wolter DJ, Hanson ND, Lister PD (2005) AmpC and OprD are not involved in the mechanism of imipenem hypersusceptibility among Pseudomonas aeruginosa isolates overexpressing the mexCD-oprJ efflux pump. Antimicrob Agents Chemother 49:4763–4766CrossRefPubMed

47.

Quale J, Bratu S, Gupta J et al (2006) Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 50:1633–1641CrossRefPubMed

48.

Wolter DJ, Hanson ND, Lister PD (2004) Insertional inactivation of oprD in clinical isolates of Pseudomonas aeruginosa leading to carbapenem resistance. FEMS Microbiol Lett 236:137–143CrossRefPubMed

49.

Akasaka T, Tanaka M, Yamaguchi A et al (2001) Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob Agents Chemother 45:2263–2268CrossRefPubMed

50.

DeRyke CA, Kuti JL, Nicolau DP (2007) Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. Diagn Microbiol Infect Dis 58:337–344CrossRefPubMed

51.

Frei CR, Wiederhold NP, Burgess DS (2008) Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. J Antimicrob Chemother 61:621–628CrossRefPubMed

52.

Ball P (2003) Adverse drug reactions: implications for the development of fluoroquinolones. J Antimicrob Chemother 51:21–27CrossRefPubMed

53.

Hocquet D, Nordmann P, El Garch F et al (2006) Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 50:1347–1351CrossRefPubMed

54.

Linares JF, López JA, Camafeita E et al (2005) Overexpression of the multidrug efflux pumps MexCD-OprJ and MexEF-OprN is associated with a reduction of type III secretion in Pseudomonas aeruginosa. J Bacteriol 187:1384–1391CrossRefPubMed

55.

Wolter DJ, Smith-Moland E, Goering RV et al (2004) Multidrug resistance associated with mexXY expression in clinical isolates of Pseudomonas aeruginosa from a Texas hospital. Diagn Microbiol Infect Dis 50:43–50CrossRefPubMed

56.

Mueller MR, Hayden MK, Fridkin SK et al (2008) Nosocomial acquisition of Pseudomonas aeruginosa resistant to both ciprofloxacin and imipenem: a risk factor and laboratory analysis. Eur J Clin Microbiol Infect Dis 27:565–570CrossRefPubMed

57.

Adams-Haduch JM, Paterson DL, Sidjabat HE et al (2008) Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. Antimicrob Agents Chemother 52:3837–3843CrossRefPubMed

58.

Jones GL, Warren RE, Skidmore SJ et al (2008) Prevalence and distribution of plasmid-mediated quinolone resistance genes in clinical isolates of Escherichia coli lacking extended-spectrum beta-lactamases. J Antimicrob Chemother 62:1245–1251CrossRefPubMed

59.

Shin JH, Jung HJ, Lee JY et al (2008) High rates of plasmid-mediated quinolone resistance QnrB variants among ciprofloxacin-resistant Escherichia coli and Klebsiella pneumoniae from urinary tract infections in Korea. Microb Drug Resist 14:221–226CrossRefPubMed

60.

El Amin N, Giske CG, Jalal S et al (2005) Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates. APMIS 113:187–196CrossRefPubMed

61.

Michéa-Hamzehpour M, Lucain C, Pechere JC (1991) Resistance to pefloxacin in Pseudomonas aeruginosa. Antimicrob Agents Chemother 35:512–518PubMed

62.

Huang H, Hancock RE (1993) Genetic definition of the substrate selectivity of outer membrane porin protein OprD of Pseudomonas aeruginosa. J Bacteriol 175:7793–7800PubMed

63.

Mahamoud A, Chevalier J, Alibert-Franco S et al (2007) Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy. J Antimicrob Chemother 59:1223–1229CrossRefPubMed

64.

Hirakata Y, Srikumar R, Poole K et al (2002) Multidrug efflux systems play an important role in the invasiveness of Pseudomonas aeruginosa. J Exp Med 196:109–118CrossRefPubMed

65.

Piddock LJV (2006) Multidrug-resistance efflux pumps—not just for resistance. Nat Rev Micro 4:629–636CrossRef

66.

Tegos GP, Masago K, Aziz F et al (2008) Inhibitors of bacterial multidrug efflux pumps potentiate antimicrobial photoinactivation. Antimicrob Agents Chemother 52:3202–3209CrossRefPubMed

67.

Schweizer HP (1998) Intrinsic resistance to inhibitors of fatty acid biosynthesis in Pseudomonas aeruginosa is due to efflux: application of a novel technique for generation of unmarked chromosomal mutations for the study of efflux systems. Antimicrob Agents Chemother 42:394–398PubMed

68.

Chuanchuen R, Beinlich K, Hoang TT et al (2001) Cross-resistance between triclosan and antibiotics in Pseudomonas aeruginosa is mediated by multidrug efflux pumps: exposure of a susceptible mutant strain to triclosan selects nfxB mutants overexpressing MexCD-OprJ. Antimicrob Agents Chemother 45:428–432CrossRefPubMed

Title: The relative contribution of efflux and target gene mutations to fluoroquinolone resistance in recent clinical isolates of Pseudomonas aeruginosa
Authors: S. A. Dunham
C. J. McPherson
A. A. Miller
Publication date: 01-03-2010
Publisher: Springer-Verlag
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 3/2010
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-009-0852-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2010

Bacteraemia with Campylobacter jejuni: no association with the virulence genes iam, cdtB, capA or virB

Modeling antibiotic resistance to project future rates: quinolone resistance in Escherichia coli

Invasive group A streptococcal infection in children: clinical manifestations and molecular characterization in a French pediatric tertiary care center

A newly described vancomycin-resistant ST412 Enterococcus faecium predominant in Greek hospitals

Overweight and obesity as risk factors for the asymptomatic carrier state of Neisseria meningitidis among a paediatric population

Infections by pandrug-resistant gram-negative bacteria: clinical profile, therapeutic management, and outcome in a series of 21 patients

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials